Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTC518 in Huntington's Disease
NCT05358717Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of votoplam in Huntington's disease (HD), sponsored by Novartis. Started Jun 2022; status: completed.
02
Drugs
votoplam
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT05358717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05358717.